FORWARD PAD IDE Study With the Shockwave Javelin IVL Catheter

Trial details

Who runs it

Shockwave Medical, Inc.

Trial code

NCT05858905

Record updated

14 July 2026

Original description

The FORWARD PAD IDE Study is a prospective, multi-center, single-arm investigational device exemption study, conducted to assess the safety and effectiveness of the Shockwave Medical Mini S Peripheral IVL System for the treatment of heavily calcified, stenotic peripheral arteries.Read full original descriptionShow less

Forward-Shifted Intravascular Lithotripsy (IVL) Technology in a Prospective, Multi-center, Single-arm Investigational Device Exemption (IDE) Study

The FORWARD PAD IDE Study is a prospective, multi-center, single-arm investigational device exemption study, conducted to assess the safety and effectiveness of the Shockwave Medical Mini S Peripheral IVL System for the treatment of heavily calcified, stenotic peripheral arteries.

General Inclusion Criteria; Age of subject is ≥ 18 years; Subject is able and willing to comply with all assessments in the study; Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and has signed the approved consent form; Estimated life expectancy > 1 year; Rutherford Clinical Category 2, 3, 4 or 5 of the target limb(s); Angiographic Inclusion Criteria; One or two target lesion(s) located in a native de novo superficial femoral, popliteal or infrapopliteal artery (above the ankle joint), in one or both limbs; Target lesion reference vessel diameter (RVD) between 2.0 mm and 7.0 mm by investigator visual estimate; Target lesion stenosis ≥70% (for vessels below the knee defined as P3 to the ankle joint) or ≥90% (for vessels above the knee) by investigator visual estimate; Target lesion length is ≤150 mm by investigator visual estimate. Target lesion can be all or part of the 150 mm treated zone; Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is <50mm in length; General Exclusion Criteria; Rutherford Clinical Category 0, 1 and 6 (target limb); History of endovascular or surgical procedure on the target limb within the last 30 days or planned within 30 days of the index procedure, with the exception of toe amputation. Note: inflow treatment of non-target lesions is allowed providing successful treatment; Subject in whom antiplatelet or anticoagulant therapy is contraindicated; Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated; Subject has known allergy to urethane, nylon, or silicone; Myocardial infarction within 60 days prior to enrollment; History of stroke within 60 days prior to enrollment; Subject has acute or chronic renal disease with eGFR <30 ml/min/1.73 m2 (using CKD-EPI formula), unless on renal replacement therapy; Subject is pregnant or nursing; Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint; Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment; Covid-19 diagnosis within 30 days; Planned use of cutting/scoring balloons, re-entry or atherectomy devices in target lesion(s) during the index procedure; Planned major amputation of target limb; Acute limb ischemia; Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot); Subject already enrolled into this study; Angiographic Exclusion Criteria; Failure to successfully treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries, defined as ≤30% residual stenosis with no serious angiographic complications (e.g. embolism); Failure to successfully treat significant non-target infra-popliteal lesions, if treated prior to treatment of target lesion(s). Successful treatment is defined as obtaining ≤50% residual stenosis with no serious angiographic complications (e.g., embolism); Target lesion includes in-stent restenosis; Evidence of aneurysm or thrombus in target vessel; No calcium or mild calcium in the target lesion; Target lesion within native or synthetic vessel grafts; Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.

ClinicalTrials.gov NCT05858905